Richard L. Hudson

Europe is lousy at reaping the commercial benefits of its R&D. To spur reform, Science|Business is preparing a “manifesto” of policy measures for technology transfer and innovation. What’s needed? A revolution.

On 26 January, in London, Science|Business organised a roundtable of executives in the biotech industry to discuss the state of the market. The consensus: investor appetite for biotech companies is on the rise.

"I didn't think they would be at this stage for decades, let alone within a year." Gerald Schatten, colleague of Korea's stem-cell celebrity, before scandal broke

Lab-supply companies are normally in the business of selling things to scientists, rather than buying. But the new CEO of Sigma-Aldrich, one of the world's largest lab-supply firms, is shopping for new ideas, new partners - and new companies to invest in.

Two New Year's resolutions for the governments around the world that have managed to gum up the economic machinery behind technological development.

Scientists are moving around as never before. And, argues Jean Guinet from the OECD, that’s not necessarily a bad thing.

A politician's gaffe highlights the gender gap in science. Political action, not talk, is what's needed to close it.

Universities are funding more campus companies. Richard L. Hudson on the rules of a very risky game.